See more : Dolfin Rubbers Limited (DOLFIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cryoport, Inc. (CYRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryoport, Inc., a leading company in the Integrated Freight & Logistics industry within the Industrials sector.
You may be interested
- Sineng Electric Co.,Ltd. (300827.SZ) Income Statement Analysis – Financial Results
- Assembly Biosciences, Inc. (ASMB) Income Statement Analysis – Financial Results
- Malaga Inc. (MLGAF) Income Statement Analysis – Financial Results
- Tatatu S.p.A. (ALTTU.PA) Income Statement Analysis – Financial Results
- Redde Northgate PLC (67GX.L) Income Statement Analysis – Financial Results
Cryoport, Inc. (CYRX)
About Cryoport, Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.26M | 237.28M | 222.61M | 78.70M | 33.94M | 19.63M | 11.95M | 7.68M | 5.88M | 3.94M | 2.66M | 1.10M | 555.64K | 475.50K | 117.96K | 35.12K | 83.56K | 67.10K | 152.30K | 271.43K |
| Cost of Revenue | 133.92M | 133.40M | 126.03M | 42.36M | 16.59M | 9.39M | 5.99M | 4.58M | 3.99M | 2.77M | 2.22M | 1.59M | 1.39M | 1.30M | 717.71K | 546.15K | 386.37K | 176.94K | 315.65K | 499.65K |
| Gross Profit | 99.33M | 103.87M | 96.58M | 36.33M | 17.35M | 10.24M | 5.97M | 3.10M | 1.89M | 1.17M | 436.96K | -487.28K | -836.82K | -827.48K | -599.75K | -511.03K | -302.81K | -109.84K | -163.35K | -228.22K |
| Gross Profit Ratio | 42.59% | 43.78% | 43.38% | 46.17% | 51.12% | 52.18% | 49.91% | 40.39% | 32.14% | 29.70% | 16.43% | -44.28% | -150.61% | -174.02% | -508.46% | -1,454.93% | -362.37% | -163.68% | -107.26% | -84.08% |
| Research & Development | 18.04M | 15.72M | 16.84M | 9.48M | 3.74M | 1.84M | 1.21M | 598.11K | 550.26K | 352.58K | 409.11K | 425.45K | 491.85K | 449.13K | 284.85K | 297.38K | 166.23K | 87.86K | 254.49K | 98.70K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 17.47M | 9.80M | 7.42M | 6.45M | 5.93M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 13.82M | 7.25M | 5.23M | 4.82M | 4.16M | 2.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.88M | 120.06M | 97.56M | 56.86M | 31.29M | 17.04M | 12.65M | 11.27M | 10.08M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Other Expenses | 49.57M | -5.52M | -2.82M | -929.00K | 772.07K | 77.63K | 14.34K | -6.77K | -9.90K | -4.27K | -13.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -630.00 | -3.00 | 0.00 |
| Operating Expenses | 214.49M | 135.78M | 114.41M | 66.34M | 35.03M | 18.88M | 13.86M | 11.87M | 10.63M | 6.76M | 5.52M | 5.84M | 6.60M | 4.77M | 3.60M | 2.68M | 2.72M | 1.99M | 1.28M | 721.50K |
| Cost & Expenses | 348.41M | 269.18M | 240.44M | 108.71M | 51.62M | 28.27M | 19.85M | 16.44M | 14.62M | 9.53M | 7.74M | 7.42M | 7.99M | 6.07M | 4.32M | 3.23M | 3.10M | 2.16M | 1.59M | 1.22M |
| Interest Income | 0.00 | 8.47M | 3.25M | 761.00K | 784.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.94K | 15.57K | 8.16K | 32.10K | 50.08K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.50M | 6.14M | 4.69M | 2.56M | 1.37M | 69.25K | 15.69K | 139.42K | 1.07M | 1.43M | 784.45K | 72.86K | 527.75K | 618.77K | 7.03M | 2.69M | 1.59M | 228.37K | 80.38K | 85.77K |
| Depreciation & Amortization | 27.49M | 22.77M | 20.25M | 9.87M | 2.42M | 857.94K | 664.83K | 374.20K | 239.23K | 197.94K | 311.59K | 393.96K | 343.03K | 245.48K | 150.09K | 81.98K | 1.34M | 111.22K | 88.75K | 92.60K |
| EBITDA | -66.36M | -6.19M | -248.91M | -20.31M | -14.49M | -8.61M | -7.21M | -13.38M | -8.51M | -5.40M | -18.47M | -5.91M | -6.96M | -5.29M | 1.53M | -13.93M | -2.93M | -1.99M | -1.35M | -857.12K |
| EBITDA Ratio | -28.45% | -15.77% | -9.28% | -39.31% | -49.80% | -43.65% | -65.90% | -109.37% | -148.77% | -142.23% | -706.79% | -538.87% | -1,274.16% | -1,122.18% | -3,424.14% | -8,773.52% | -2,005.44% | -2,958.25% | -887.85% | -315.11% |
| Operating Income | -115.16M | -31.90M | -17.83M | -30.01M | -17.68M | -8.64M | -7.89M | -8.77M | -8.74M | -5.59M | -5.08M | -6.32M | -7.43M | -5.60M | -4.20M | -3.20M | -3.02M | -2.10M | -1.44M | -949.72K |
| Operating Income Ratio | -49.37% | -13.45% | -8.01% | -38.13% | -52.07% | -44.05% | -66.02% | -114.16% | -148.60% | -142.12% | -190.92% | -574.67% | -1,338.05% | -1,177.08% | -3,558.31% | -9,098.32% | -3,613.77% | -3,123.99% | -946.12% | -349.89% |
| Total Other Income/Expenses | 15.81M | -3.19M | -256.01M | -2.73M | -594.90K | -891.03K | -1.36K | -4.34M | -1.08M | -1.43M | -14.49M | -56.38K | -396.65K | -553.60K | -1.45M | -13.51M | -1.54M | -228.37K | -80.38K | -87.59K |
| Income Before Tax | -99.35M | -35.09M | -273.84M | -32.74M | -18.27M | -9.54M | -7.89M | -13.11M | -9.82M | -7.03M | -19.56M | -6.38M | -7.83M | -6.15M | -5.65M | -16.70M | -4.56M | -2.32M | -1.52M | -1.04M |
| Income Before Tax Ratio | -42.59% | -14.79% | -123.02% | -41.60% | -53.83% | -48.59% | -66.03% | -170.70% | -166.89% | -178.52% | -735.50% | -579.79% | -1,409.43% | -1,293.51% | -4,789.89% | -47,555.95% | -5,459.83% | -3,464.31% | -998.90% | -382.17% |
| Income Tax Expense | 239.00K | 2.24M | 1.69M | -45.00K | 61.58K | 19.95K | 5.14K | 5.67K | 3.63K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 800.00 | 800.00 |
| Net Income | -99.59M | -37.33M | -275.53M | -32.69M | -18.33M | -9.56M | -7.90M | -13.11M | -9.82M | -7.03M | -19.57M | -6.38M | -7.83M | -6.15M | -5.65M | -16.71M | -4.56M | -2.33M | -1.52M | -1.04M |
| Net Income Ratio | -42.69% | -15.73% | -123.77% | -41.54% | -54.01% | -48.69% | -66.08% | -170.77% | -166.95% | -178.56% | -735.56% | -579.94% | -1,409.72% | -1,293.84% | -4,791.25% | -47,560.50% | -5,461.75% | -3,466.70% | -999.42% | -382.46% |
| EPS | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| EPS Diluted | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| Weighted Avg Shares Out | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.20M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
| Weighted Avg Shares Out (Dil) | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.22M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
Cryoport Remains A Disappointing Prospect
Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since...
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for...
Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki -...
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.31 per share a year ago.
Cryoport Reports Third Quarter 2024 Financial Results
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235...
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024
NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third...
Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services
Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™ Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and...
TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics
Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in...
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas , Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the...
Source: https://incomestatements.info
Category: Stock Reports